Leerink Swann began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note released on Friday morning, MarketBeat reports. The brokerage issued an outperform rating and a $2.00 target price on the biopharmaceutical company’s stock.

RGLS has been the topic of a number of other reports. Needham & Company LLC reissued a hold rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Zacks Investment Research lowered shares of Regulus Therapeutics from a buy rating to a hold rating in a report on Tuesday, September 19th. Finally, Wedbush restated an outperform rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Regulus Therapeutics currently has a consensus rating of Hold and an average target price of $2.46.

Shares of Regulus Therapeutics (NASDAQ RGLS) traded up $0.06 on Friday, hitting $1.24. The stock had a trading volume of 1,561,500 shares, compared to its average volume of 1,037,825. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $2.60. The company has a market cap of $128.90, a PE ratio of -0.92 and a beta of 1.55.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in Regulus Therapeutics by 12.1% in the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock worth $182,000 after acquiring an additional 19,934 shares during the last quarter. FMR LLC raised its holdings in Regulus Therapeutics by 0.5% in the 2nd quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after acquiring an additional 37,489 shares during the last quarter. GSA Capital Partners LLP raised its holdings in Regulus Therapeutics by 44.8% in the 3rd quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 63,100 shares during the last quarter. Quantitative Investment Management LLC purchased a new position in Regulus Therapeutics in the 2nd quarter worth approximately $103,000. Finally, Goldman Sachs Group Inc. raised its holdings in Regulus Therapeutics by 189.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 240,890 shares during the last quarter. Institutional investors own 59.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Leerink Swann Begins Coverage on Regulus Therapeutics (RGLS)” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/01/08/leerink-swann-begins-coverage-on-regulus-therapeutics-rgls.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.